General MedicationsORALStandard
AUGTYRO
REPOTRECTINIB
Standard Dose
160MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview AUGTYRO is listed in Drugs@FDA under application 218213 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient REPOTRECTINIB Form and strength CAPSULE;ORAL - 160MG Sponsor BRISTOL Submission history Latest submission status date: 2024-06-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview AUGTYRO is listed in Drugs@FDA under application 218213 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient REPOTRECTINIB Form and strength CAPSULE;ORAL - 160MG Sponsor BRISTOL Submission history Latest submission status date: 2024-06-13 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.